Population pharmacokinetic analysis of vancomycin in patients with hematological malignancies

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 12, 2005, Pages 4934-4941

  Santos Buelga, Dolores ^a   Del Mar Fernandez De Gatta, María ^a   Herrera, Emma V ^b   Dominguez Gil, Alfonso ^a,c   García, María José ^a  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b BENEMÉRITA UNIVERSIDAD AUTÓNOMA DE PUEBLA   (Mexico)

^c HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMPHOTERICIN; ANTINEOPLASTIC AGENT; VANCOMYCIN;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ARTICLE; BAYES THEOREM; BODY WEIGHT; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CREATININE CLEARANCE; DRUG CLEARANCE; DRUG DISTRIBUTION; FEMALE; HEMATOLOGIC MALIGNANCY; HIGH RISK POPULATION; HODGKIN DISEASE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; PHARMACOKINETICS; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADULT; ANTI-BACTERIAL AGENTS; DRUG MONITORING; HEMATOLOGIC NEOPLASMS; HUMANS; MIDDLE AGED; MODELS, BIOLOGICAL; VANCOMYCIN;

EID: 28844447571     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.12.4934-4941.2005     Document Type: Article

References (53)

1. Abbott Laboratories. 1991. AbbottBase Pharmacokinetics System. Abbott Laboratories, Diagnostic Division, Abbott Park, Ill.
2. Akaike, H. 1979. A Bayesian extension of the minimum AIC procedure of autoregressive model fitting. Biometrika 66:237-242.
3. Barret, J. S. 2002. Population pharmacokinetics, p. 315-356. In R. D. Schoenwald (ed.), Pharmacokinetics in drug discovery and development. CRC Press, Boca Raton, Fla.
4. Beal, S. L., and L. B. Sheiner. 1989. NONMEM user's guides. NONMEM project group. University of California, San Francisco.
5. Bertino, J. S., Jr., L. A. Booker, P. Franck, and B. Rybicki. 1991. Gentamicin pharmacokinetics in patients with malignancies. Antimicrob. Agents Chemother. 35:1501-1503.
6. Birt, J. K., and M. H. H. Chandler. 1990. Using clinical data to determine vancomycin dosing parameters. Ther. Drug Monit. 12:206-209.
7. Burton, M. E., D. L. Gentle, and R. Vasko. 1989. Evaluation of a Bayesian method for predicting vancomycin dosing. DICP 23:294-300.
8. Centers for Disease Control and Prevention. 1998. Summary of notifiable diseases-United States, 1997. Morbid. Mortal. Wkly. Rep. 46:1-87.
9. Chang, D. 1995. Influence of malignancy on the pharmacokinetics of vancomycin in infants and children. Pediatr. Infect. Dis. J. 14:667-673.
10. Cockcroft, D. W., and M. H. Gault. 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41.
11. D'Argenio, D. Z., and A. Schumitzky. 1992. ADAPT II user's manual. Biomedical simulation resource. University of South California, Los Angeles.
12. Davis, R. L., D. Lehmann, C. A. Stidley, and J. Neidhart. 1991. Amikacin pharmacokinetics in patients receiving high-dose cancer chemotherapy. Antimicrob. Agents Chemother. 35:944-947.
13. Drusano, G. L. 2003. Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin. Infect. Dis. 36(Suppl. 1):542-550.
14. Ducharme, M. P., R. L. Slaughter, and D. J. Edwards. 1994. Vancomycin pharmacokinetics in a patient population: effect of age, gender and body weight. Ther. Drug Monit. 16:513-518.
15. Eastern Cooperative Oncology Group. 17 February 2000. Ecog performance status. http://www.ecog.org/general/perf_stat.html. Accessed 2 December 2004.
16. Elting, L. S., E. B. Rubenstein, K. V. I. Rolston, and G. P. Bodey. 1997. Outcomes of bacteriemia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin. Infect. Dis. 25:247-259.
17. Fernandez de Gatta, M. M., I. Fruns, J. M. Hernandez, D. Caballero, J. F. San Miguel, J. Martinez Lanao, and A. Dominguez-Gil Hurle. 1993. Vancomycin pharmacokinetics and dosage requirements in hematologic malignancies. Clin. Pharm. 12:515-520.
18. Fernandez de Gatta, M. M., I. Fruns, M. V. Calvo, J. M. Lanao, and A. Dominguez-Gil. 1996. Influence of pharmacokinetic model on vancomycin peak concentration target. Ther. Drug Monit. 18:145-148.
19. Frimodt-Moller, N. 2002. How predictive is PK/PD for antibacterial agents? Int. J. Antimicrob. Agents 19:333-339.
20. Golper, T. A., H. M. Noonan, L. Elzinga, D. Gilbert, R. Brummett, J. L. Anderson, and W. M. Bennett. 1988. Vancomycin pharmacokinetics, renal handling, and nonrenal clearances in normal human subjects. Clin. Pharmacol. Ther. 43:565-570.
21. Hoog, M., R. C. Schoemaker, J. W. Mouton, and J. N. van den Anker. 2000. Vancomycin population pharmacokinetics in neonates. Clin. Pharmacol. Ther. 67:360-367.
22. Hurst, A. K., M. A. Yoshinaga, G. H. Mitani, K. A. Foo, R. W. Jelliffe, and E. C. Harrison. 1990. Application of a Bayesian method to monitor and adjust vancomycin dosage regimens. Antimicrob. Agents Chemother. 34: 1165-1171.
23. Jelliffe, R. W. 1973. Creatinine clearance: bedside estimate. Ann. Intern. Med. 79:604-605.
24. Jonsson, E. N., and M. O. Karlsson. 1999. Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput. Methods Prog. Biomed. 58:51-64.
25. Kitzes-Cohen, R., D. Farin, G. Piva, S. Ivry, R. Sharony, R. Amar, and G. Uretzky. 2000. Pharmacokinetics of vancomycin administered as prophylaxis before cardiac surgery. Ther. Drug Monit. 22:661-667.
26. Leonard, A. E., and M. S. Boro. 1994. Vancomycin pharmacokinetics in middle-aged and elderly men. Am. J. Hosp. Pharm. 51:798-800.
27. Levey, A. S., J. P. Bosch, J. B. Lewis, T. Greene, N. Rogers, D. Roth, et al. 1999. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann. Intern. Med. 130:461-470.
28. Marra, F., B. Carins, and P. Jewesson. 1996. Vancomycin serum concentration monitoring. The middle ground is best. Clin. Drug Investig. 12:105-118.
29. Matzke, G. R., R. W. McGory, C. E. Halstenson, and W. F. Keane. 1984. Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob. Agents Chemother. 25:433-437.
30. Moellering, R. C., D. J. Krogstand, and D. T. Greenblatt. 1981. Vancomycin in patients with impaired renal function; a nomogram for dosage. Ann. Intern. Med. 94:343-346.
31. Mosteller, R. D. 1987. Simplified calculation of body-surface area. N. Engl. J. Med. 317:1098.
32. Mungall, D., J. Heissler, and M. Kaltenbach. 1995. Computer applications in clinical pharmacokinetics and pharmacodynamics, p. 415-463. In H. Derendorf and G. Hochhaus (ed.), Handbook of pharmacokinetic/pharmacodynamic correlation. CRC Press, Boca Raton, Fla.
33. Pea, F., L. Porreca, M. Baraldo, and M. Furlanut. 2000. High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures. J. Antimicrob. Chemother. 45:329-335.
34. Pea, F., D. Poz, M. Baraldo, and M. Furlanut. 2000. Optimisation of vancomycin regimen in neutropenic haematological patients with normal renal function. Clin. Drug Investig. 19:213-218.
35. Pea, F., P. Viale, A. Candoni, F. Pavan, L. Pagani, D. Damiani, M. Casini, and M. Furlanut. 2004. Teicoplanin in patients with acute leukaemia and febrile neutropenia: a special population benefiting from higher dosages. Clin. Pharmacokinet. 43:405-415.
36. Polk, R. 1999. Optimal use of modern antibiotics: emerging trends. Clin. Infect. Dis. 29:264-274.
37. Romano, S., M. M. Fernandez de Gatta, M. V. Calvo, D. Caballero, A. Dominguez-Gil, and J. M. Lanao. 1999. Population pharmacokinetics of amikacin in patients with haematological malignancies. J. Antimicrob. Chemother. 44:235-242.
38. Rushing, T. A., and P. J. Ambrose. 2001. Clinical application and evaluation of vancomycin dosing in adult. J. Pharm. Technol. 17:33-38.
39. Rybak, M. J., and S. C. Boike. 1986. Monitoring vancomycin therapy. Drug Intell. Clin. Pharm. 20:757-761.
40. Scaglione, F. 2002. Can PK/PD be used in everyday clinical practice. Int. J. Antimicrob. Agents 19:349-353.
41. Seay, R. E., R. C. Brundage, P. D. Jensen, C. G. Schilling, and B. E. Edgren. 1994. Population pharmacokinetics of vancomycin in neonates. Clin. Pharmacol. Ther. 56:169-175.
42. Sheiner, L. B., and S. L. Beal. 1981. Some suggestions for measuring predictive performance. J. Pharmacokinet. Biopharm. 9:503-512.
43. SPSS. 2000. SPSS for Windows release 10.0.7 user's manual. SPSS, Chicago, Ill.
44. Tsubaki, T., S. Goodin, W. G. Leader, and M. H. Chandler. 1993. Estimation of creatinine clearance in patients with gynaecologic cancer. Clin. Pharm. 12:685-690.
45. Vinks, A. A. 2002. The application of population pharmacokinetic modeling to individualized antibiotic therapy. Int. J. Antimicrob. Agents 19:313-322.
46. Viscoli, C., and E. Castagnola. 2002. Treatment of febrile neutropenia: what is new? Curr. Opin. Infect. Dis. 15:377-382.
47. Vozeh, S., P. O. Maitre, and D. R. Stanski. 1990. Evaluation of population (NONMEM) pharmacokinetic parameter estimates. J. Pharmacokinet. Biopharm. 18:161-163.
48. Wilhelm, M. P., and L. Estes. 1999. Symposium on antimicrobial agents-part XII. Vancomycin. Mayo Clin. Proc. 74:928-935.
49. Wu, G., and M. Furlanut. 1998. Prediction of serum vancomycin concentrations using one-, two- and three-compartment models with implemented population pharmacokinetic parameters and with the Bayesian method. J. Pharm. Pharmacol. 50:851-856.
50. Yasuhara, M., T. Iga, H. Zenda, K. Okumura, T. Oguma, Y. Yano, and R. Hori. 1998. Population pharmacokinetics of vancomycin in Japanese adult patients. Ther. Drug Monit. 20:139-148.
51. Yasuhara, M., T. Iga, H. Zenda, K. Okumura, T. Oguma, Y. Yano, and R. Hori. 1998. Population pharmacokinetics of vancomycin in Japanese pediatric patients. Ther. Drug Monit. 20:612-618.
52. Zaera, S., J. Hermida, and J. C. Tutor. 2002. Effect of analytical inaccuracy on dose adjustment for vancomycin, amikacin, and tobramycin using the Abbottbase Pharmacokinetic Systems. Ther. Drug Monit. 24:696-700.
53. Zeitany, R. G., N. S. El Saghir, C. R. Santhosh-Kumar, and M. A. Sigmon. 1990. Increased aminoglycoside dosage requirements in hematologic malignancy. Antimicrob. Agents Chemother. 34:702-708.